Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.68 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL253849 | 1.00 | EGFR (0.68) | EGFRERBB2ERBB4 | |
| SCHEMBL254450 | 1.00 | EGFR (0.68) | EGFRERBB2ERBB4 | |
| SCHEMBL245219 | 1.00 | EGFR (0.68) | EGFRERBB2ERBB4 | |
| SCHEMBL245873 | 0.91 | EGFR (0.69) | EGFRERBB2ERBB4 | |
| SCHEMBL243454 | 0.91 | EGFR (0.69) | EGFRERBB2ERBB4 | |
| SCHEMBL254362 | 0.91 | EGFR (0.69) | EGFRERBB2ERBB4 | |
| SCHEMBL253552 | 0.91 | EGFR (0.69) | EGFRERBB2ERBB4 | |
| SCHEMBL3325797 | 0.81 | EGFR (0.64) | EGFRERBB2ERBB4 | |
| SCHEMBL2253765 | 0.80 | EGFR (0.86) | EGFRERBB2ERBB4 | |
| SCHEMBL18387769 | 0.79 | EGFR (1.00) | EGFRERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172373-A1 | QUINAZOLINE COMPOUNDS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-04 | — | — | US | claimed |
| EP-2590966-A1 | QUINAZOLINE COMPOUNDS | Hutchison Medipharma Limited (CN) | 2013-05-15 | — | — | EP | claimed |
| WO-2012000356-A1 | QUINAZOLINE COMPOUNDS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-01-05 | — | — | WO | claimed |
| US-9168253-B2 | Quinazoline compounds | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-10-27 | — | — | US | disclosed |
| US-20130172373-A1 | QUINAZOLINE COMPOUNDS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-04 | — | — | US | disclosed |
| EP-2590966-A1 | QUINAZOLINE COMPOUNDS | Hutchison Medipharma Limited (CN) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012000356-A1 | QUINAZOLINE COMPOUNDS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172373-A1 | QUINAZOLINE COMPOUNDS | EGFR, ABL1, ERBB2 | EGFR 1/4885ERBB2 3/4885ERBB4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.